Description
Andrew D. Krahn, MD, FHRS discusses this article with guests Jason D. Roberts, MD and Julia Cadrin-Tourigny, MD, PhD, CCDS. Clinical guidelines recommend regular screening for arrhythmogenic right ventricular cardiomyopathy (ARVC) to monitor at-risk relatives, resulting in a significant burden on clinical resources. Prioritizing relatives on their probability of developing definite ARVC may provide more efficient patient care.
Learning Objectives
- The aim of this study was to determine the predictors and probability of ARVC development over time among at-risk relatives.
Article Authors and Podcast Contributors
Article Authors
Steven A. Muller, Alessio Gasperetti, Laurens P. Bosman, Amand F. Schmidt, Annette F. Baas, Ahmad S. Amin, Arjan C. Houweling,Arthur A.M. Wilde, Paolo Compagnucci, Mattia Targetti, Michela Casella, Leonardo Calò, Claudio Tondo, Pim van der Harst, Folkert W. Asselbergs, J. Peter van Tintelen, Marish I.F.J. Oerlemans, Anneline S.J.M. te Riele
Podcast Contributors
Andrew D. Krahn, MD, FHRS of University of British Columbia
Jason D. Roberts, MD of McMaster University
Julia Cadrin-Tourigny, MD, PhD, CCDS of Montreal Heart Institute
Disclosure Policy
ACE Disclosure Policy
The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.
Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.
ACCME Definition:
*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
All relevant financial relationships have been mitigated.Host Disclosure(s):
A. Krahn: Honoraria/Speaking/Consulting Fee: Medtronic, Inc
Contributor Disclosure(s):
J. Roberts: Honoraria/Speaking/Consulting Fee: Ionis Pharmaceuticals
J. Cadrin-Tourigny: Honoraria/Speaking/Consulting Fee: BMS/Pfizer Alliance, Bayer Healthcare Pharmaceuticals, Tenaya Therapeutics
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.